The global transfection reagents & equipment market is estimated to be USD 1.47 billion in 2024 and is expected to reach USD 3.35 billion by 2035, with a CAGR of 7.81% during the forecast period 2025-2035. The market will grow due to rising cancer and infectious disease prevalence, increased adoption of CRISPR and gene editing technologies, growing demand for gene and cell therapy, improvements in transfection technologies, and expanding research and development activities.
Recent advancements in transfection techniques, including electroporation and liposome-mediated transfection, have greatly improved the efficiency of molecular delivery. These innovative methods not only enhance transfection success rates but also prioritize improved safety profiles and reduced cytotoxicity for cells. Furthermore, the development of cutting-edge instruments that provide enhanced control and precision has empowered researchers to achieve higher transfection success rates. A notable example of innovation in this field is the recent introduction by Altogen Biosystems. In August 2023, the company launched a novel targeted reagent designed specifically for the treatment of pulmonary diseases. This reagent facilitates the direct delivery of biomolecules to the lungs, safely and effectively providing small molecules, DNA, RNA, and proteins. As a result, it represents a significant advancement in addressing serious respiratory conditions, such as cystic fibrosis and lung cancer.
By product, the reagents segment accounted for the highest revenue-grossing segment in the global transfection reagents & equipment market in 2024 owing to the increasing demand for high-quality transfection reagents in gene therapy and cell-based research, as well as their widespread use in molecular biology studies for gene expression and protein production. For instance, Amerigo Scientific revealed a novel transfection reagent in June 2024 that can effectively transfer protein, RNA, siRNA, and DNA into cells. In addition to the frequent usage of kits and reagents in different experimental techniques, businesses that offer reasonably priced reagents are anticipated to dominate the transfection reagent and equipment market. Additionally, the equipment segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising adoption of advanced transfection devices that offer improved efficiency, precision, and scalability for high-throughput applications in research and drug discovery.
By method, the electroporation segment accounted for the highest revenue-grossing segment in the global transfection reagents & equipment market in 2024 owing to the method's ability to efficiently transfect a wide range of cell types, including hard-to-transfect cells, and its effectiveness in achieving high transfection efficiency without the need for chemical reagents. For instance, the Alliance for mRNA Medicines (AMM) and MaxCyte, a business that develops cell-engineering technologies, collaborated in November 2023. AMM advocates for next-generation mRNA and encoding RNA vaccines and treatments with the goal of enhancing public health and patient outcomes worldwide. Additionally, the particle bombardment segment is predicted to grow at the fastest CAGR during the forecast period owing to its utility in delivering nucleic acids and biomolecules into plant and animal cells, as well as its expanding applications in gene therapy research and crop improvement.
By application, the gene expression studies segment accounted for the highest revenue-grossing segment in the global transfection reagents & equipment market in 2024 owing to the increased use of transfection techniques in exploring gene function, analyzing genetic pathways, and For instance, Polyplus was acquired from private investors by Sartorius and its subsidiary Sartorius Stedim Biotech in April 2023 for around USD 2.6 billion. This French pharmaceutical company provides state-of-the-art upstream technologies for gene and cell therapies, such as plasmid DNA, transfection, and premium GMP-grade DNA/RNA delivery reagents. Additionally, the biomedical research segment is predicted to grow at the fastest CAGR during the forecast period owing to its expanding role in developing therapies for genetic diseases, cancers, and immune-related disorders, driving demand for advanced transfection technologies.
By end-user, the pharmaceutical and biotechnological companies segment accounted for the highest revenue-grossing segment in the global transfection reagents & equipment market in 2024 owing to the extensive use of transfection in drug discovery, biologics production, and gene therapy research by pharmaceutical and biotech firms. For instance, Asimov, Inc. introduced the LV Edge Packaging System in April 2024, which reaches E8 TU/mL and enables single plasmid transfection. Furthermore, clones up to E9 TU/mL can be produced using the recently launched, completely stable LV Edge Producer cell line production service without the requirement for temporary transfection. Additionally, the academic and Research Institutes segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased funding and grants for genetic and cellular research, along with the growing number of research projects focused on molecular biology and genetic engineering.
North American region is anticipated to have the highest revenue share during the forecast period owing to the strong presence of leading biotechnology and pharmaceutical companies, significant investment in genetic research, and well-established healthcare infrastructure that supports advanced transfection technologies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapid expansion of biotechnological and pharmaceutical industries, increasing government support for research and development, and rising demand for gene therapy and personalized medicine. For instance, Cellular Origins and Cell and Gene Therapy Catapult collaborated in May 2024 to demonstrate the advantages of automating the production of cell and gene therapies. This partnership seeks to address scaling issues and progress the field at CGT Catapult's Stevenage Manufacturing Innovation Centre by utilizing Cellular Origin's Constellation robotic automation technology.
This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.
Recent advancements in transfection techniques, including electroporation and liposome-mediated transfection, have greatly improved the efficiency of molecular delivery. These innovative methods not only enhance transfection success rates but also prioritize improved safety profiles and reduced cytotoxicity for cells. Furthermore, the development of cutting-edge instruments that provide enhanced control and precision has empowered researchers to achieve higher transfection success rates. A notable example of innovation in this field is the recent introduction by Altogen Biosystems. In August 2023, the company launched a novel targeted reagent designed specifically for the treatment of pulmonary diseases. This reagent facilitates the direct delivery of biomolecules to the lungs, safely and effectively providing small molecules, DNA, RNA, and proteins. As a result, it represents a significant advancement in addressing serious respiratory conditions, such as cystic fibrosis and lung cancer.
By product, the reagents segment accounted for the highest revenue-grossing segment in the global transfection reagents & equipment market in 2024 owing to the increasing demand for high-quality transfection reagents in gene therapy and cell-based research, as well as their widespread use in molecular biology studies for gene expression and protein production. For instance, Amerigo Scientific revealed a novel transfection reagent in June 2024 that can effectively transfer protein, RNA, siRNA, and DNA into cells. In addition to the frequent usage of kits and reagents in different experimental techniques, businesses that offer reasonably priced reagents are anticipated to dominate the transfection reagent and equipment market. Additionally, the equipment segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising adoption of advanced transfection devices that offer improved efficiency, precision, and scalability for high-throughput applications in research and drug discovery.
By method, the electroporation segment accounted for the highest revenue-grossing segment in the global transfection reagents & equipment market in 2024 owing to the method's ability to efficiently transfect a wide range of cell types, including hard-to-transfect cells, and its effectiveness in achieving high transfection efficiency without the need for chemical reagents. For instance, the Alliance for mRNA Medicines (AMM) and MaxCyte, a business that develops cell-engineering technologies, collaborated in November 2023. AMM advocates for next-generation mRNA and encoding RNA vaccines and treatments with the goal of enhancing public health and patient outcomes worldwide. Additionally, the particle bombardment segment is predicted to grow at the fastest CAGR during the forecast period owing to its utility in delivering nucleic acids and biomolecules into plant and animal cells, as well as its expanding applications in gene therapy research and crop improvement.
By application, the gene expression studies segment accounted for the highest revenue-grossing segment in the global transfection reagents & equipment market in 2024 owing to the increased use of transfection techniques in exploring gene function, analyzing genetic pathways, and For instance, Polyplus was acquired from private investors by Sartorius and its subsidiary Sartorius Stedim Biotech in April 2023 for around USD 2.6 billion. This French pharmaceutical company provides state-of-the-art upstream technologies for gene and cell therapies, such as plasmid DNA, transfection, and premium GMP-grade DNA/RNA delivery reagents. Additionally, the biomedical research segment is predicted to grow at the fastest CAGR during the forecast period owing to its expanding role in developing therapies for genetic diseases, cancers, and immune-related disorders, driving demand for advanced transfection technologies.
By end-user, the pharmaceutical and biotechnological companies segment accounted for the highest revenue-grossing segment in the global transfection reagents & equipment market in 2024 owing to the extensive use of transfection in drug discovery, biologics production, and gene therapy research by pharmaceutical and biotech firms. For instance, Asimov, Inc. introduced the LV Edge Packaging System in April 2024, which reaches E8 TU/mL and enables single plasmid transfection. Furthermore, clones up to E9 TU/mL can be produced using the recently launched, completely stable LV Edge Producer cell line production service without the requirement for temporary transfection. Additionally, the academic and Research Institutes segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased funding and grants for genetic and cellular research, along with the growing number of research projects focused on molecular biology and genetic engineering.
North American region is anticipated to have the highest revenue share during the forecast period owing to the strong presence of leading biotechnology and pharmaceutical companies, significant investment in genetic research, and well-established healthcare infrastructure that supports advanced transfection technologies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapid expansion of biotechnological and pharmaceutical industries, increasing government support for research and development, and rising demand for gene therapy and personalized medicine. For instance, Cellular Origins and Cell and Gene Therapy Catapult collaborated in May 2024 to demonstrate the advantages of automating the production of cell and gene therapies. This partnership seeks to address scaling issues and progress the field at CGT Catapult's Stevenage Manufacturing Innovation Centre by utilizing Cellular Origin's Constellation robotic automation technology.
This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.
Report Scope:
- Base Year: 2024
- Forecast Period: 2025-2035
- Study Coverage
- Market Forecast by Product, Method, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Transfection Reagents & Equipment Market Report 2024 - 2035
Transfection Reagents & Equipment Market Analysis & Forecast by Product 2024 - 2035 (Revenue USD Bn)
- Reagents
- Equipment
Transfection Reagents & Equipment Market Analysis & Forecast by Method 2024 - 2035 (Revenue USD Bn)
- Electroporation
- Liposomes
- Particle Bombardment
- Microinjection
- Adenoviral Vectors
- Calcium Phosphate
- DEAE-dextran
- Magnetic Beads
- Activated Dendrimers
- Laserfection
Transfection Reagents & Equipment Market Analysis & Forecast by Application 2024 - 2035 (Revenue USD Bn)
- Gene Expression Studies
- Protein Production
- Transgenic Models
- Therapeutic Delivery
- Cancer Research
- Biomedical Research
Transfection Reagents & Equipment Market Analysis & Forecast by End-User Industry 2024 - 2035 (Revenue USD Bn)
- Academic And Research Institutes
- Pharmaceutical And Biotechnology Companies
Transfection Reagents & Equipment Market Analysis & Forecast by Region 2024 - 2035 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Transfection Reagents & Equipment Market: Product Estimates & Trend Analysis
8. Transfection Reagents & Equipment Market: Method Estimates & Trend Analysis
9. Transfection Reagents & Equipment Market: Application Estimates & Trend Analysis
10. Transfection Reagents & Equipment Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Transfection Reagents & Equipment Market
13. Europe Global Transfection Reagents & Equipment Market
14. Asia Pacific Global Transfection Reagents & Equipment Market
15. Latin America Global Transfection Reagents & Equipment Market
16. MEA Global Transfection Reagents & Equipment Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Sigma-Aldrich (Merck KGaA)
- Lonza Group
- Promega Corporation
- F. Hoffmann-La Roche AG
- Qiagen N.V.
- Santa Cruz Biotechnology, Inc.
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- New England Biolabs, Inc. (NEB)
- MaxCyte, Inc.
- Transposagen Biopharmaceuticals, Inc.
- Cell Biolabs, Inc.
- Invitrogen (Thermo Fisher Scientific)
- Altogen Biosystems
Table Information
Report Attribute | Details |
---|---|
Published | December 2024 |
Forecast Period | 2023 - 2034 |
Estimated Market Value ( USD | $ 1.47 Billion |
Forecasted Market Value ( USD | $ 3.35 Billion |
Compound Annual Growth Rate | 7.8% |
Regions Covered | Global |
No. of Companies Mentioned | 15 |